Dear Chris Young:
We appreciate your interest and enthusiasm regarding cyclophosphamide, a life-sustaining and well-established chemotherapy agent.
There currently is ample supply of cyclophosphamide, and Baxter
continues to make it available to its customer base, including Accentia,
the makers of Revimmune. It’s important to note that the intended and
approved use of cyclophosphamide is as a chemotherapy agent, and Baxter does not currently have approval for cyclophosphamide’s use in addressing multiple sclerosis (MS). However, as you know, Revimmune is
being studied for the potential treatment of MS.
We are always supportive of research which may lead to additional
therapeutic options for patients and recognize the promising potential
of the use of cyclophosphamide for autoimmune diseases based on
While Baxter manufactures cyclophosphamide, we are not currently
conducting clinical trials for MS nor do we play a role in determining
which patients may enroll in investigator-led trials.
We are sensitive to the critical role cyclophosphamide plays in
patients’ treatment and will continue to follow the important work being
done to treat MS, as well as continue to evaluate how we may be able to
contribute in this area.
We are committed to ensuring the safe and continuous supply of
cyclophosphamide for appropriate patient use and appreciate you taking
the time to contact us.
Center for One Baxter
Baxter Healthcare Corporation
T 800.422.9837 toll-free
T 847.948.4770 direct
F 800-568.5020 toll-free
F 847.948.3642 direct
**I don't know if I believe it all or not.**